Skip to main content
STI & HIV 2023 World Congress Main banner
Final Program


Icon Legend

  1. Home

  • Tuesday, Jul 25th
    10:30 – 10:45 CST
    O1.3 - Increasing rates of non-albicans Candida species and fluconazole resistant Candida albicans in women with recurrent vulvovaginal candidiasis in a UK region
    Location: Chicago 8
    Primary Presenter: Jennifer CL Ratner, MSc – The Leeds Teaching Hospitals NHS Trust
    Clinical Science
  • Tuesday, Jul 25th
    10:30 – 10:45 CST
    O3.3 - Detection of Treponema pallidum at asymptomatic oral, anal and vaginal sites in men and women reporting contact with syphilis.
    Location: Chicago 10
    Primary Presenter: Ei T. Aung, MBChB (she/her/hers) – Melbourne Sexual Health Centre, The Alfred Health , Melbourne, Victoria
    Clinical Science
  • Tuesday, Jul 25th
    11:15 – 11:30 CST
    O1.6 - Spontaneous resolution and treatment outcomes in men with Trichomonas vaginalis infection
    Location: Chicago 8
    Primary Presenter: Christina A. Muzny, MD, MSPH (she/her/hers) – Division of Infectious Diseases, University of Alabama at Birmingham
    Clinical Science
  • Tuesday, Jul 25th
    11:15 – 11:30 CST
    O3.6 - Rapid Plasma Reagin (RPR) sero-reversion after treatment and its association with Prior Treponema Pallidum infection: analysis from the PICASSO cohort among people with early syphilis in Peru
    Location: Chicago 10
    Primary Presenter: Edward Michael Reyes-Diaz, Sr., MD, Ms(c) (he/him/his) – Centro de Investigación Interdisciplinaria en Sexualidad, SIDA y Sociedad, Universidad Peruana Cayetano Heredia
    Clinical Science
  • Tuesday, Jul 25th
    15:30 – 15:45 CST
    O4.5 - Efficacy of minocycline for the treatment of Mycoplasma genitalium
    Location: Chicago 8
    Primary Presenter: Lenka A. Vodstrcil, PhD (she/her/hers) – Monash University and Melbourne Sexual Health Centre
    Clinical Science
  • Tuesday, Jul 25th
    15:30 – 15:45 CST
    O5.5 - Pritelivir for the treatment of resistant HSV infections in immunocompromised patients: update on an ongoing Phase 3 trial and Early Access Program
    Location: Chicago 9
    Primary Presenter: Alexander Birkmann, PhD – AiCuris Anti-Infective Cures AG
    Clinical Science
  • Wednesday, Jul 26th
    10:15 – 10:30 CST
    O7.2 - Routine Pharyngeal Gonorrhea Test-of-Cure: Does It Detect Treatment Failures?
    Location: Chicago 8
    Primary Presenter: Laura A. S Quilter, MD, MPH (she/her/hers) – U.S. Centers for Disease Control and Prevention
    Clinical Science
  • Wednesday, Jul 26th
    10:30 – 10:45 CST
    O7.3 - The impact of near-to-patient testing of sexually transmitted infections on clinical practice and antimicrobial stewardship: the NEPTUNE study
    Location: Chicago 8
    Primary Presenter: Lenka A. Vodstrcil, PhD (she/her/hers) – Monash University and Melbourne Sexual Health Centre
    Clinical Science
  • Wednesday, Jul 26th
    11:00 – 11:15 CST
    O8.5 - Validation of an Easy to Administer Algorithm to Define Penicillin Allergy Status in STI Clinic Outpatients
    Location: Chicago 9
    Primary Presenter: Rebecca A. Lillis, MD – Louisiana State University Health Sciences Center, New Orleans
    Clinical Science
  • Wednesday, Jul 26th
    14:45 – 15:00 CST
    LB2.2 - Does screening for Neisseria gonorrhoeae and Chlamydia trachomatis affect the incidence of these infections in MSM taking HIV-PrEP? Results from a randomized, multicenter, controlled trial
    Location: Michigan A+B
    Primary Presenter: Thibaut Vanbaelen, MD – Institute Of Tropical Medicine, Antwerp, Belgium
    Clinical Science
  • Thursday, Jul 27th
    10:30 – 10:45 CST
    O15.3 - Do we understand rectal chlamydia infections in women? A study including different anatomical sites, quantification and viability of Chlamydia trachomatis in two Swedish STI-clinics
    Location: Sheraton 1
    Primary Presenter: Mimmi Wänn – Department of Clinical Microbiology, Uppsala University Hospital, Uppsala, Sweden
    Clinical Science
  • Thursday, Jul 27th
    11:00 – 11:15 CST
    O13.5 - Characteristics of mpox positive, versus mpox negative, and mpox unsuspected clients from the Centre of Sexual Health, Public Health Service of Amsterdam, 20 May to 15 September 2022
    Location: Michigan A/B
    Primary Presenter: Henry de Vries, Md PhD – Public Health Service Amsterdam and Amsterdam University Medical Centre
    Clinical Science
  • Thursday, Jul 27th
    11:15 – 11:30 CST
    O13.6 - Rectal and Pharyngeal Mpox PCR Testing of Men Who Have Sex with Men (MSM) Suggests that Rectal Testing is More Sensitive than Lesion Testing and that Most Infections Are Asymptomatic
    Location: Michigan A/B
    Primary Presenter: Matthew R. Golden, MD, MPH – University of Washington
    Clinical Science